Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 7/20 | 0.57 |
| ▸ | DRD2 | P14416 | 5/20 | 0.57 |
| ▸ | DRD3 | P35462 | 5/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7469793 | 0.91 | DRD4 (0.57) | DRD4DRD2DRD3HTR7SIGMAR1 | |
| SCHEMBL8745020 | 0.90 | ITGB3 (0.52) | DRD4DRD2DRD3HTR7MAPT | |
| SCHEMBL3243301 | 0.90 | LMNA (0.60) | DRD4DRD2NPSR1TDP1L3MBTL1 | |
| SCHEMBL2327148 | 0.88 | DRD4 (0.55) | DRD4DRD2DRD3HTR7SIGMAR1 | |
| Hydrochloric Acid SCHEMBL2688554 | 0.87 | DRD4 (0.54) | DRD4DRD2DRD3HTR7SIGMAR1 | |
| SCHEMBL8048603 | 0.85 | ALDH1A1 (0.61) | TDP1L3MBTL1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL11164060 | 0.84 | DRD4 (0.55) | DRD4DRD2DRD3HTR7SIGMAR1 | |
| SCHEMBL4520079 | 0.84 | ALDH1A1 (0.68) | DRD4DRD2DRD3HTR7MAPT | |
| SCHEMBL4521810 | 0.84 | DRD4 (0.54) | DRD4DRD2DRD3HTR7SIGMAR1 | |
| SCHEMBL9117228 | 0.83 | PRMT1 (0.54) | DRD4DRD2DRD3HTR7SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560460-B2 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1417190-B1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-7115607-B2 | Substituted piperazinyl amides and methods of use | AMGEN INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1417190-A1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | Amgen Inc. (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20030220324-A1 | Substituted piperazines and methods of use | AMGEN INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003009850-A1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC. (US) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220324-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | DRD4 1157/4885DRD2 666/4885DRD3 828/4885 |
| US-20070265248-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | DRD4 1157/4885DRD2 666/4885DRD3 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.